LT3060660T - Rekombinantiniai glikoproteinai ir jų naudojimas - Google Patents

Rekombinantiniai glikoproteinai ir jų naudojimas

Info

Publication number
LT3060660T
LT3060660T LTEPPCT/US2014/061789T LT14796346T LT3060660T LT 3060660 T LT3060660 T LT 3060660T LT 14796346 T LT14796346 T LT 14796346T LT 3060660 T LT3060660 T LT 3060660T
Authority
LT
Lithuania
Prior art keywords
glycroteins
recombinant
recombinant glycroteins
Prior art date
Application number
LTEPPCT/US2014/061789T
Other languages
English (en)
Lithuanian (lt)
Inventor
Karen Lee
Christopher HWANG
Christine Demaria
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of LT3060660T publication Critical patent/LT3060660T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70592—CD52
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
LTEPPCT/US2014/061789T 2013-10-23 2014-10-22 Rekombinantiniai glikoproteinai ir jų naudojimas LT3060660T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361894879P 2013-10-23 2013-10-23
US201361901942P 2013-11-08 2013-11-08
PCT/US2014/061789 WO2015061464A2 (en) 2013-10-23 2014-10-22 Recombinant glycoproteins and uses thereof

Publications (1)

Publication Number Publication Date
LT3060660T true LT3060660T (lt) 2021-07-26

Family

ID=51871299

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2014/061789T LT3060660T (lt) 2013-10-23 2014-10-22 Rekombinantiniai glikoproteinai ir jų naudojimas

Country Status (33)

Country Link
US (2) US11208644B2 (enExample)
EP (2) EP3060660B1 (enExample)
JP (2) JP6837334B2 (enExample)
KR (2) KR102298080B1 (enExample)
CN (3) CN112852784A (enExample)
AU (2) AU2014340152A1 (enExample)
BR (1) BR112016008086A2 (enExample)
CA (1) CA2927852A1 (enExample)
CL (1) CL2016000961A1 (enExample)
CR (1) CR20160225A (enExample)
DK (1) DK3060660T3 (enExample)
DO (1) DOP2016000079A (enExample)
EA (1) EA034515B1 (enExample)
ES (1) ES2882562T3 (enExample)
HR (1) HRP20211197T1 (enExample)
HU (1) HUE055236T2 (enExample)
IL (2) IL245255B (enExample)
LT (1) LT3060660T (enExample)
MX (1) MX392532B (enExample)
MY (2) MY197247A (enExample)
NZ (1) NZ720384A (enExample)
PE (1) PE20160723A1 (enExample)
PH (1) PH12016500708B1 (enExample)
PL (1) PL3060660T3 (enExample)
PT (1) PT3060660T (enExample)
RS (1) RS62171B1 (enExample)
SG (2) SG11201602932WA (enExample)
SI (1) SI3060660T1 (enExample)
TN (1) TN2016000140A1 (enExample)
TW (3) TWI793159B (enExample)
UA (1) UA119857C2 (enExample)
UY (1) UY35794A (enExample)
WO (1) WO2015061464A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
JP7114485B2 (ja) * 2016-05-18 2022-08-08 モデルナティエックス インコーポレイテッド ファブリー病の治療のためのα-ガラクトシダーゼAをコードするポリヌクレオチド
KR102712926B1 (ko) 2016-10-20 2024-10-07 상가모 테라퓨틱스, 인코포레이티드 파브리병의 치료를 위한 방법 및 조성물
US11357834B2 (en) 2017-01-10 2022-06-14 Amicus Therapeutics, Inc. Recombinant α-galactosidase A for treatment of Fabry disease
CN113423419A (zh) 2019-01-04 2021-09-21 桑格摩生物治疗股份有限公司 用于治疗法布里病的方法和组合物
WO2025092951A1 (en) * 2023-11-03 2025-05-08 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant adeno-associated viral vectors for treating fabry disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
NZ506214A (en) * 1996-09-13 2002-11-26 Transkaryotic Therapies Inc Therapy for alpha-galactosidase A deficiency
EP1027069B1 (en) 1997-10-29 2006-07-26 Genzyme Corporation Gene therapy for gaucher disease
US20020081654A1 (en) * 2000-04-07 2002-06-27 Sandrin Mauro Sergio Targeting hydrolase enzymes
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7133354B2 (en) 2002-08-26 2006-11-07 Qualcomm Incorporated Synchronization techniques for a wireless system
TWI328614B (en) * 2002-12-23 2010-08-11 Bristol Myers Squibb Co Product quality enhancement in mammalian cell culture processes for protein production
CN100522988C (zh) * 2003-04-09 2009-08-05 诺和诺德公司 糖peg化方法及由该方法生产的蛋白质/肽
JP5967861B2 (ja) * 2007-04-03 2016-08-10 オキシレイン ユーケー リミテッド 分子のグリコシル化
US20110117601A1 (en) * 2007-08-31 2011-05-19 Markus Haberger Glycosylation Profile Analysis
US9034341B2 (en) * 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
DK2865751T3 (en) * 2010-03-02 2017-01-09 Protalix Ltd Stabilized alpha-galactosidase and uses thereof
US20120178105A1 (en) 2011-01-10 2012-07-12 Genzyme Corporation Detection of globotriaosylceramide (glc) in human urine samples using an antibody sandwich
EP2665814B1 (en) * 2011-01-20 2017-05-17 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
WO2013055888A2 (en) * 2011-10-12 2013-04-18 Synageva Biopharma Corp. Recombinant human naglu protein and uses thereof
EP2620506A1 (en) 2012-01-25 2013-07-31 Arla Foods Amba Method of producing a galacto-oligosaccharide-containing composition
TWI528785B (zh) 2013-02-08 2016-04-01 瑞昱半導體股份有限公司 立體影像的調整裝置及其方法
AU2014226126B2 (en) 2013-03-08 2019-02-14 Genzyme Corporation Continuous purification of therapeutic proteins

Also Published As

Publication number Publication date
CR20160225A (es) 2016-06-24
TW201900873A (zh) 2019-01-01
TW201610163A (zh) 2016-03-16
US11208644B2 (en) 2021-12-28
AU2020294173A1 (en) 2021-02-11
UA119857C2 (uk) 2019-08-27
JP7296327B2 (ja) 2023-06-22
AU2014340152A1 (en) 2016-06-09
TN2016000140A1 (en) 2017-10-06
SG11201602932WA (en) 2016-05-30
CN114606217A (zh) 2022-06-10
MY197247A (en) 2023-06-08
MX2016005321A (es) 2017-01-05
RS62171B1 (sr) 2021-08-31
UY35794A (es) 2015-05-29
IL272609B (en) 2022-03-01
IL272609A (en) 2020-03-31
KR102298080B1 (ko) 2021-09-06
CL2016000961A1 (es) 2017-02-03
KR102479886B1 (ko) 2022-12-20
SG10201803366PA (en) 2018-05-30
JP6837334B2 (ja) 2021-03-03
DOP2016000079A (es) 2016-05-30
MX392532B (es) 2025-03-24
DK3060660T3 (da) 2021-09-13
WO2015061464A2 (en) 2015-04-30
PH12016500708B1 (en) 2023-03-01
KR20160066550A (ko) 2016-06-10
EP3060660B1 (en) 2021-06-23
ES2882562T3 (es) 2021-12-02
TWI793159B (zh) 2023-02-21
TWI642782B (zh) 2018-12-01
TW202332774A (zh) 2023-08-16
JP2016538840A (ja) 2016-12-15
EP3060660A2 (en) 2016-08-31
JP2020089379A (ja) 2020-06-11
NZ720384A (en) 2022-04-29
MY178632A (en) 2020-10-19
EA201690826A1 (ru) 2016-08-31
US20220064617A1 (en) 2022-03-03
EA034515B1 (ru) 2020-02-14
EP3778884A1 (en) 2021-02-17
CA2927852A1 (en) 2015-04-30
KR20210111880A (ko) 2021-09-13
PE20160723A1 (es) 2016-08-01
PT3060660T (pt) 2021-08-06
SI3060660T1 (sl) 2021-09-30
PH12016500708A1 (en) 2016-05-30
CN112852784A (zh) 2021-05-28
HUE055236T2 (hu) 2021-11-29
US20160264953A1 (en) 2016-09-15
WO2015061464A3 (en) 2015-09-03
CN105916984A (zh) 2016-08-31
BR112016008086A2 (pt) 2017-10-03
PL3060660T3 (pl) 2021-12-06
IL245255A0 (en) 2016-06-30
IL245255B (en) 2020-02-27
HRP20211197T1 (hr) 2021-11-12

Similar Documents

Publication Publication Date Title
IL276106A (en) Garp-binding proteins and their uses
LT2970303T (lt) Pakeistieji ksantinai ir jų panaudojimo metodai
DK3043784T3 (da) Arylethere og anvendelser deraf
LT2968443T (lt) Hepcidino analogai ir jų naudojimas
IL244744B (en) Matrix metalloproteinase cleavable polypeptides and uses thereof
LT3019483T (lt) Terapiniu požiūriu aktyvūs junginiai ir jų panaudojimo būdai
LT3363438T (lt) Pakeistieji 2-azabiciklai ir jų panaudojimas kaip oreksino receptorių moduliatorių
DK2920313T3 (da) Rekombinante adenovira og anvendelse deraf
LT3003039T (lt) Metil/fluor-piridinil-metoksi grupės pakeistieji piridinono-piridinilo junginiai ir fluor-pirimidinil-metoksi grupės pakeistieji piridinono-piridinilo junginiai
LT3071597T (lt) Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
DK3058936T3 (da) Peptidsammensætning og anvendelser deraf
LT3311845T (lt) Terapinės polimerinės nanodalelės ir jų gamybos bei panaudojimo būdai
DK3053119T3 (da) Papirløs anvendelse
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
LT2989088T (lt) Dolastatino 10 ir auristatinų dariniai
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
LT3030519T (lt) Tricikliniai benzoksaborolo junginiai ir jų naudojimas
DK3029038T3 (da) Tetrazolinonforbindelse og anvendelse deraf
DK2956698T5 (da) Bindestrimler
LT3083677T (lt) Naujos eukariotinės ląstelės ir dominančio polipeptido rekombinantinės raiškos būdai
DK2969005T3 (da) Attenuerede influenzavira og -vacciner
DK3060660T3 (da) Rekombinante glycoproteiner og anvendelser deraf
EP3051144A4 (en) COMPRESSORS AND CHARGERS
HRP20180520T1 (hr) Suncobran
BR112015024661A2 (pt) silo e silo elevado